
    
      The objective of the Clinical Experience Investigation (CEI) is to collect following data to
      characterise safety and efficacy of LYMPARZA Tablets 100mg and 150mg (LYMPARZA) in usual
      post-marketing use.

        1. Development of adverse drug reactions (ADRs)

        2. Factors which may affect safety and efficacy of LYMPARZA

        3. Development of adverse drug reactions (ADRs) unexpected from "Precautions for Use" of
           the LYMPARZA JPI
    
  